显著降低即刻假体乳房再造的假体丢失率:质量保证方案与完整审计
单中心乳腺肿瘤整形单元通过回顾性审计(2012年5月至2014年7月,77例再造,54例患者)发现3个月假体丢失率为14%(11例丢失)。引入包含超过25项方案变更的循证干预束后,前瞻性再审计(2015年4月至2017年12月,129例再造,106例患者)显示3个月无假体丢失。Fisher精确检验显示假体丢失率下降具有统计学意义(P < 0.00001)。
要点
- 干预前3个月假体丢失率为14%(77例再造中11例丢失)。
- 引入超过25项方案变更的干预束后,再审计129例再造3个月无假体丢失。
- 假体丢失率下降具有统计学意义(P < 0.00001)。
核心结论
- 遵循该循证干预束可将即刻假体乳房再造的假体丢失率降至极低水平,远低于国家目标。
- 该方案有望改善全国范围内的结局。
研究设计与样本
- 单中心乳腺肿瘤整形单元的审计研究,包括回顾性审计和前瞻性再审计。
- 回顾性审计纳入2012年5月至2014年7月的77例再造(54例患者)。
- 前瞻性再审计纳入2015年4月至2017年12月的129例再造(106例患者)。
- 干预为包含超过25项方案变更的循证干预束,涉及术前、术中和术后干预。
主要发现
- 回顾性审计中,77例再造有11例在3个月时假体丢失(14%)。
- 再审计中,129例再造在3个月时无假体丢失。
- Fisher精确检验显示假体丢失率下降具有统计学意义(P < 0.00001)。
关键数值与推荐
- 国家乳房切除术与乳房再造审计及假体乳房再造审计数据显示3个月全国假体丢失率为9%。
- 国家肿瘤整形最佳实践指南引用<5%的目标。
- 干预前本中心3个月假体丢失率为14%(11/77)。
- 干预后3个月假体丢失率为0%(0/129)。
临床怎么用
- 采用包含术前、术中和术后干预的循证干预束,包括超过25项方案变更。
- 建立涉及微生物学、手术室人员、感染控制和外科医生的团队。
- 通过前瞻性审计持续监测3个月假体丢失率。
局限性
- 研究为单中心审计,样本量有限(干预前77例再造,干预后129例再造)。
- 原文未报告混杂因素控制或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immediate implant-based breast reconstruction (IBR) rates have increased considerably with the advent of acellular dermal matrices. Implant loss is a significant complication and is costly to patients and the NHS. National Mastectomy and Breast Reconstruction Audit and Implant-Based Breast Reconstruction Audit data have demonstrated national implant loss rate of 9% at 3 months. National Oncoplastic Guidelines for Best Practice cite a < 5% target. We aimed to reduce implant loss by introducing a protocol with pre-, intra- and post-operative interventions. METHODS: Audit of IBR at a single oncoplastic breast unit was commenced and implant loss at 3 months was recorded (May 2012-July 2014). Patients were identified from a prospectively maintained database, and case notes were examined by identifying factors associated with implant loss. A team involving microbiology, theatre staff, infection control and surgeons was established. A novel, evidence-based intervention bundle, including more than 25 protocol changes, was introduced. Prospective re-audit of IBR (April 2015-December 2017) was completed following introduction of the new protocol and implant loss was recorded at 3 months. RESULTS: The first retrospective audit of 77 reconstructions (54 patients) demonstrated 11 implant losses at 3 months (14%). Re-audit, post-intervention, comprised 129 reconstructions (106 patients) with no implant loss at 3 months. Fisher's exact analysis revealed statistically significant reduction in implant loss rate (P < 0.00001) following protocol introduction. CONCLUSIONS: Implant loss rate following IBR can be reduced to an exceptionally low level, well below national targets, by adhering to this evidence-based intervention bundle. Our protocol could improve outcomes nationally.
引用
- Knight HJ, Musgrove JJ, Youssef MMG, et al. Significantly reducing implant loss rates in immediate implant-based breast reconstruction: A protocol and completed audit of quality assurance. J Plast Reconstr Aesthet Surg. 2019. PMID: 32008945. doi:10.1016/j.bjps.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。